Business UpdateJul 14, 2026, 05:21 PM
Kestra Medical Technologies Details Cardiac Recovery System
AI Summary
Kestra Medical Technologies, Ltd. filed its 10-K, detailing its Cardiac Recovery System platform, anchored by the ASSURE Wearable Cardioverter Defibrillator (WCD). The company, which completed its IPO in March 2025, highlights its differentiated product design, strong clinical evidence, and significant market opportunity. Kestra aims to expand its market share in the U.S. and internationally, leveraging its technology to improve patient outcomes in cardiovascular disease.
Key Highlights
- Completed initial public offering on March 7, 2025.
- ASSURE WCD FDA approved on July 27, 2021.
- Protected nearly 40,000 patients with ASSURE WCD as of April 30, 2026.
- Global WCD market reached approximately $1.1 billion in 2025.
- Estimated annual U.S. addressable market for ASSURE WCD is approximately $10 billion.
- Estimated annual international addressable market is approximately $14 billion.
- ASSURE WCD reported a low false alarm rate of 6% in ACE-PAS, projected to 3%.
- Medicare reimbursement for ASSURE WCD is approximately $3,589 per month.
Price Impact
More from KMTS